Floatz logo

Pegargiminase

Diffuse Midline Glioma, H3 K27M-Mutant

Sabine Mueller, MD, PhDprotein_peptidePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Diffuse Midline Glioma, H3 K27M-Mutant cohort.

Asset / SponsorPhaseRating
Ribociclib
Nationwide Children's Hospital
Phase 2B
Everolimus
Nationwide Children's Hospital
Phase 2CCC
Olutasidenib
Rigel Pharmaceuticals
Phase 2CCC
Sonidegib
St. Jude Children's Research Hospital
Phase 1CC
FILGRASTIM
St. Jude Children's Research Hospital
Phase 1CC

View all 14 →

Same molecule, other indications

Pegargiminase is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
60 / 100
View asset →
neoplasmDormant
B
Indicative ·
56 / 100
View asset →
cutaneous melanomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →